EGFR and breast carcinoma: Examples include rituximab directed against CD20 on malignant B cells, trastuzumab against Her-2/neu on, e.g., subsets of breast cancer cells, and cetuximab, recognizing epidermal growth factor receptor (EGFR) that is overexpressed on many epithelial cancers.